Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
IOBT

IOBT - IO Biotech, Inc. Stock Price, Fair Value and News

$0.31-0.02 (-6.06%)
Market Closed

38/100

IOBT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

38/100

IOBT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.33

Target 3M

$0.36

Target 6M

$0.35

IOBT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IOBT Price Action

Last 7 days

47.6%

Last 30 days

-54.4%

Last 90 days

-63.9%

Trailing 12 Months

-67.4%

IOBT RSI Chart

IOBT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IOBT Valuation

Market Cap

22.3M

Price/Earnings (Trailing)

-0.25

Price/Sales (Trailing)

16.58

EV/EBITDA

-0.09

Price/Free Cashflow

-0.28

IOBT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.33

Target 3M

$0.36

Target 6M

$0.35

IOBT Fundamentals

IOBT Revenue

Revenue (TTM)

3.5M

IOBT Earnings

Earnings (TTM)

-88.4M

Earnings Growth (Yr)

65.11%

Earnings Growth (Qtr)

68.04%

IOBT Profitability

EBT Margin

-2540.65%

Return on Equity

-9.7K%

Return on Assets

-221.14%

Free Cashflow Yield

-363.45%

IOBT Investor Care

Shares Dilution (1Y)

9.21%

Diluted EPS (TTM)

-1.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20253.5M000
20246.5M6.6M5.9M4.7M
20232.4M3.5M4.7M5.9M
20220001.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About IO Biotech, Inc.

IOBT
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
 CEO
 WEBSITEiobiotech.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES57

IO Biotech, Inc. Frequently Asked Questions

IOBT is the stock ticker symbol of IO Biotech, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of IO Biotech, Inc. is 22.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check IOBT's fair value in chart for subscribers.

The fair value guage provides a quick view whether IOBT is over valued or under valued. Whether IO Biotech, Inc. is cheap or expensive depends on the assumptions which impact IO Biotech, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IOBT.

As of Wed Jan 28 2026, IOBT's PE ratio (Price to Earnings) is -0.25 and Price to Sales (PS) ratio is 16.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IOBT PE ratio will change depending on the future growth rate expectations of investors.